Published in Mult Scler on September 19, 2008
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology (2014) 4.74
Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary. Neurology (2015) 2.08
"Undiagnosing" multiple sclerosis: the challenge of misdiagnosis in MS. Neurology (2012) 1.94
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology (2015) 1.82
Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol (2013) 1.79
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol (2016) 1.73
A population-based study of neuromyelitis optica in Caucasians. Neurology (2011) 1.58
The history of neuromyelitis optica. J Neuroinflammation (2013) 1.25
Reduced NAA-levels in the NAWM of patients with MS is a feature of progression. A study with quantitative magnetic resonance spectroscopy at 3 Tesla. PLoS One (2010) 1.18
Multiple Large Tumefactive MS Plaques in a Young Man: A Diagnostic Enigma and Therapeutic Challenge. Case Rep Radiol (2012) 1.10
The radiologically isolated syndrome: take action when the unexpected is uncovered? J Neurol (2010) 1.09
New insights into neuromyelitis optica. J Clin Neurol (2011) 1.09
Brain abnormalities in neuromyelitis optica spectrum disorder. Mult Scler Int (2012) 1.07
Local mechanical properties of white matter structures in the human brain. Neuroimage (2013) 1.07
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol (2015) 1.05
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol (2015) 1.04
Spinal cord MRI in multiple sclerosis--diagnostic, prognostic and clinical value. Nat Rev Neurol (2015) 1.01
Diffusion-weighted imaging in noncompressive myelopathies: a 33-patient prospective study. J Neurol (2010) 0.98
Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm (2015) 0.96
Anti-aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disorders. PLoS One (2013) 0.95
Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future. Expert Rev Clin Immunol (2014) 0.94
Concurrence of multiple sclerosis and brain tumors. Front Neurol (2015) 0.94
New approaches in the management of multiple sclerosis. Drug Des Devel Ther (2010) 0.92
CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult Scler (2012) 0.92
Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features. Mult Scler (2012) 0.91
Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis. AJNR Am J Neuroradiol (2015) 0.90
Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis. Brain (2015) 0.90
Neuromyelitis optica in Austria in 2011: to bridge the gap between neuroepidemiological research and practice in a study population of 8.4 million people. PLoS One (2013) 0.89
MS Prevalence and Patients' Characteristics in the District of Braga, Portugal. Neurol Res Int (2015) 0.88
Multiple sclerosis imaging: recent advances. J Neurol (2012) 0.85
Association between neuromyelitis optica and tuberculosis in a Chinese population. BMC Neurol (2014) 0.85
Neuroimaging in multiple sclerosis: neurotherapeutic implications. Neurotherapeutics (2011) 0.85
Central Nervous System Idiopathic Inflammatory Demyelinating Disorders in South Americans: A Descriptive, Multicenter, Cross-Sectional Study. PLoS One (2015) 0.84
Practice patterns of US neurologists in patients with CIS, RRMS, or RIS: A consensus study. Neurol Clin Pract (2012) 0.84
Neuromyelitis optica spectrum disorders associated with other autoimmune diseases. Rheumatol Int (2014) 0.84
Symptomatic paroxysmal dysarthria-ataxia in demyelinating diseases. J Neurol (2010) 0.84
"Central vessel sign" on 3T FLAIR* MRI for the differentiation of multiple sclerosis from migraine. Ann Clin Transl Neurol (2015) 0.83
Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome. Brain (2014) 0.83
A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis. J Neurol (2011) 0.83
Kappa free light chains: diagnostic and prognostic relevance in MS and CIS. PLoS One (2014) 0.83
Neuromyelitis optica and neuromyelitis optica spectrum disorder: Natural history and long-term outcome, an Indian experience. J Neurosci Rural Pract (2015) 0.83
The incidence of clinically isolated syndrome in a multi-ethnic cohort. J Neurol (2014) 0.83
Demyelinating and thrombotic diseases of the central nervous system: common pathogenic and triggering factors. Front Neurol (2015) 0.82
Autoantibodies and Sjogren's Syndrome in multiple sclerosis, a reappraisal. PLoS One (2013) 0.81
Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study. J Neurol (2015) 0.81
Unanticipated demyelinating pathology of the CNS. Nat Rev Neurol (2009) 0.80
Effects of formalin fixation on magnetic resonance indices in multiple sclerosis cortical gray matter. J Magn Reson Imaging (2010) 0.80
Two Cases of Acute Disseminated Encephalomyelitis Following Vaccination Against Human Papilloma Virus. Intern Med (2016) 0.79
Acute necrotizing encephalopathy (ANE1): rare autosomal-dominant disorder presenting as acute transverse myelitis. J Neurol (2013) 0.79
Venocentric Lesions: An MRI Marker of MS? Front Neurol (2013) 0.79
Guidelines for differential diagnosis of suspected multiple sclerosis. Nat Clin Pract Neurol (2009) 0.79
Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients. Neurol Sci (2013) 0.79
Intrathecal, polyspecific antiviral immune response in oligoclonal band negative multiple sclerosis. PLoS One (2012) 0.79
The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol (2016) 0.79
The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study. Neurology (2016) 0.78
Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis. Neurohospitalist (2013) 0.78
Short-term evolution of spinal cord damage in multiple sclerosis: a diffusion tensor MRI study. Neuroradiology (2012) 0.78
Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS. J Neurol (2009) 0.78
Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials. Neurology (2013) 0.77
The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. J Neurol (2016) 0.76
Progressive ascending myelopathy: atypical forms of multiple sclerosis or what else? J Neurol (2011) 0.76
Metabolic dysfunctions in multiple sclerosis: implications as to causation, early detection, and treatment, a case control study. BMC Neurol (2015) 0.76
Neuromyelitis optica spectrum disease characteristics in Isfahan, Iran: A cross-sectional study. J Res Med Sci (2017) 0.75
Targeted treatment of brainstem neurohistiocytosis guided by urinary cell-free DNA. Neurol Neuroimmunol Neuroinflamm (2016) 0.75
Clinically Isolated Syndromes: Clinical Characteristics, Differential Diagnosis, and Management. Noro Psikiyatr Ars (2015) 0.75
Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study. PLoS One (2017) 0.75
Optimizing multiple sclerosis diagnosis: gene expression and genomic association. Ann Clin Transl Neurol (2015) 0.75
Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study. J Neurol (2014) 0.75
Predictors of Conversion to Multiple Sclerosis in Patients with Clinical Isolated Syndrome Using the 2010 Revised McDonald Criteria. ISRN Neurol (2012) 0.75
Systemic Lupus Erythematosus (SLE) Complicated by Neuromyelitis Optica (NMO - Devic's Disease): Clinic-Pathological Report and Review of the Literature. Clin Med Insights Case Rep (2014) 0.75
Oligoclonal Bands in Cerebrospinal Fluid of Black Patients with Multiple Sclerosis. Biomed Res Int (2015) 0.75
Post-traumatic acute disseminated encephalomyelitis. Radiol Case Rep (2015) 0.75
Summary of eye examinations of 284 patients with multiple sclerosis. Int J MS Care (2012) 0.75
Analysis of Lymphocytic DNA Damage in Early Multiple Sclerosis by Automated Gamma-H2AX and 53BP1 Foci Detection: A Case Control Study. PLoS One (2016) 0.75
Improving outcomes in multiple sclerosis through early diagnosis and effective management. Prim Care Companion CNS Disord (2012) 0.75
Moyamoya disease mimicking the first attack of multiple sclerosis. J Neurol (2017) 0.75
Demyelinating encephalomyeloradiculitis with Balò-like lesions. J Neurol (2010) 0.75
Small-area distribution of multiple sclerosis incidence in western France: in search of environmental triggers. Int J Health Geogr (2017) 0.75
Clinically isolated syndrome presenting as paroxysmal dysarthria: a rare but typical presentation. Neurol Sci (2014) 0.75
Serum Glutamate Is a Predictor for the Diagnosis of Multiple Sclerosis. ScientificWorldJournal (2017) 0.75
Paediatric clinically isolated syndromes: report of seven cases, differential diagnosis and literature review. Childs Nerv Syst (2015) 0.75
New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol (1983) 26.67
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Revised diagnostic criteria for neuromyelitis optica. Neurology (2006) 17.57
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18
The spectrum of neuromyelitis optica. Lancet Neurol (2007) 11.83
Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology (1996) 10.26
The clinical course of neuromyelitis optica (Devic's syndrome). Neurology (1999) 8.03
PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS. Ann N Y Acad Sci (1965) 6.34
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 4.55
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med (2000) 4.50
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
Brain abnormalities in neuromyelitis optica. Arch Neurol (2006) 4.28
Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology (2007) 4.23
Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol (2008) 3.95
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
Acute fulminant demyelinating disease: a descriptive study of 60 patients. Arch Neurol (2007) 3.81
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med (2002) 3.74
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol (2007) 3.47
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol (2006) 3.26
NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology (2008) 3.21
The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain (1987) 3.15
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol (2006) 2.80
MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol (2006) 2.44
Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology (2002) 2.41
Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol (1993) 2.23
Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients. Ann Neurol (1993) 2.18
Multiple sclerosis in the Japanese population. Lancet Neurol (2003) 2.15
Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry (1996) 2.02
Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain (1990) 2.00
Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain (2007) 1.93
Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile. J Neurol Neurosurg Psychiatry (2008) 1.84
NMO-IgG in the diagnosis of neuromyelitis optica. Neurology (2007) 1.77
Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci (2006) 1.52
Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler (2007) 1.45
Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology (2006) 1.42
Neuromyelitis optica: changing concepts. J Neuroimmunol (2007) 1.39
Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. J Neurol (2004) 1.38
Acute disseminated encephalomyelitis in children: outcome and prognosis. Neuropediatrics (2003) 1.33
Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 Tesla. AJNR Am J Neuroradiol (2007) 1.30
Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology (1998) 1.26
Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol (2004) 1.20
Multiple sclerosis mimicking primary brain tumor. Arch Pathol Lab Med (1987) 1.18
Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol (2007) 1.17
Recurrence of acute disseminated encephalomyelitis at the previously affected brain site. Arch Neurol (2001) 1.13
Fulminant monophasic multiple sclerosis, Marburg's type. J Neurol Neurosurg Psychiatry (1990) 1.09
Malignant monophasic multiple sclerosis or "Marburg's disease". Neurology (1988) 1.07
ADEM: distinct disease or part of the MS spectrum? Neurology (2001) 1.03
Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations. Mult Scler (2004) 1.00
MRI and magnetization transfer imaging changes in the brain and cervical cord of patients with Devic's neuromyelitis optica. Neurology (1999) 0.98
Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler (2003) 0.97
Magnetization transfer and diffusion tensor MRI show gray matter damage in neuromyelitis optica. Neurology (2004) 0.95
Balo's concentric sclerosis: new observations on lesion development. Ann Neurol (1985) 0.93
Some clinical and pathologic observations on chronic myelopathy: a variant of multiple sclerosis. J Neurol Neurosurg Psychiatry (1990) 0.88
Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization. Mult Scler (2005) 0.88
The spectrum of disseminated encephalomyelitis. Clin Neurol Neurosurg (2006) 0.85
MRI features of pediatric multiple sclerosis. Neurology (2007) 0.84
Long-term brain magnetic resonance imaging changes after optic neuritis in patients without clinically definite multiple sclerosis. Arch Neurol (2004) 0.82
A longitudinal MR study of the presymptomatic phase in a patient with clinically definite multiple sclerosis. AJNR Am J Neuroradiol (1999) 0.82
Neuromyelitis optica. Arch Neurol (2003) 0.82
Recurrent ADEM or MS? Intern Med (2004) 0.79
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Revised diagnostic criteria for neuromyelitis optica. Neurology (2006) 17.57
Multiple sclerosis. N Engl J Med (2000) 12.69
Structure of the replicative form of bacteriphage phi X174. VI. Studies on alkali-denatured double-stranded phi X DNA. J Mol Biol (1968) 11.10
Structure of the replicative form of bacteriophage phi-X-174. VII. Renaturation of denatured double-stranded phi-X DNA. J Mol Biol (1969) 10.46
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol (1996) 10.39
Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology (1996) 10.26
The clinical course of neuromyelitis optica (Devic's syndrome). Neurology (1999) 8.03
Mammalian cell fusion: studies on the regulation of DNA synthesis and mitosis. Nature (1970) 5.90
Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med (1998) 4.65
HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA (2000) 4.62
Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum (2001) 4.60
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 4.55
Studies on mustard gas (betabeta'-dichlorodiethyl sulphide) and some related compounds: 5. The fate of injected mustard gas (containing radioactive sulphur) in the animal body. Biochem J (1946) 4.41
Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain (1999) 4.41
The neurological manifestations of systemic lupus erythematosus. Medicine (Baltimore) (1968) 4.40
Immunological aspects of demyelinating diseases. Annu Rev Immunol (1992) 4.39
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
Mammalian cell fusion: induction of premature chromosome condensation in interphase nuclei. Nature (1970) 4.21
Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res (2001) 4.12
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med (2000) 3.98
Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. Neurology (2010) 3.98
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst (2000) 3.81
The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler (1999) 3.71
Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica (1997) 3.67
Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat Med (1997) 3.65
Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol (1992) 3.53
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology (2005) 3.45
Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology (2009) 3.43
Regulation of the mammalian pineal by non-rod, non-cone, ocular photoreceptors. Science (1999) 3.41
A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res (2001) 3.37
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci U S A (1998) 3.35
A gender gap in autoimmunity. Science (1999) 3.33
Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology (2011) 3.30
A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature (1989) 3.27
The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2003) 3.21
NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology (2008) 3.21
Isolation of virus related to SV40 from patients with progressive multifocal leukoencephalopathy. N Engl J Med (1972) 3.09
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology (1996) 2.94
Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology (2007) 2.88
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology (2006) 2.75
White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J Neurol Neurosurg Psychiatry (2002) 2.72
Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol (1999) 2.61
Age-dependent resistance to viral encephalitis: studies of infections due to Sindbis virus in mice. J Infect Dis (1972) 2.56
The King-Devick test as a determinant of head trauma and concussion in boxers and MMA fighters. Neurology (2011) 2.51
Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology (2004) 2.50
Pathogenesis of viral infections of the nervous system. N Engl J Med (1968) 2.48
Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology (2007) 2.47
EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol (2010) 2.45
The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature (1995) 2.44
Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology (1992) 2.41
Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology (2002) 2.41
Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia. Hum Mol Genet (2000) 2.40
Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology (2002) 2.36
Controversy in primary care: Should asymptomatic haemochromatosis be treated? BMJ (2000) 2.36
A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells/. Nature (1994) 2.35
MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology (2010) 2.33
A quantitative assay for DNA-DNA hybrids using membrane filters. Biochem Biophys Res Commun (1966) 2.32
Role of the immune response in recovery from Sindbis virus encephalitis in mice. J Immunol (1977) 2.32
Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology (2007) 2.32
Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler (2010) 2.30
Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology (2008) 2.29
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology (2011) 2.26
Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology (2011) 2.26
Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Ann Neurol (1996) 2.22
Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol (1994) 2.21
Loss of suppressor T cells in active multiple sclerosis. Analysis with monoclonal antibodies. N Engl J Med (1980) 2.21
Measles virus-specific T4+ human cytotoxic T cell clones are restricted by class II HLA antigens. J Immunol (1984) 2.21
Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology (1998) 2.17
MRI findings in Susac's syndrome. Neurology (2003) 2.17
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17